Immunome, Inc. IMNM
19.07 USD +0.42 (+2.25%)
At closeNov 11, 2026, 4:00 PM EST
19.06 -0.01 -0.05%
After hours · Nov 11, 4:00 PM ET
18.71 Day range 19.29
16.11 52-week range 30.06
- YTD
- -11.22%
- 1 year
- +8.85%
News
benzinga.com Immunome Analysts Cut Their Forecasts After Q3 Results Immunome Inc (NASDAQ:IMNM) on Monday posted a wider-than-expected loss for the third quarter.
benzinga.com Immunome Analysts Cut Their Forecasts After Q3 Results Immunome posted a wider Q3 loss than expected, shares fell 4.6%, and analysts cut price targets despite oncology pipeline progress.
benzinga.com Stifel Maintains Hold on Immunome, Lowers Price Target to $23 Stifel analyst Dara Azar maintains Immunome (NASDAQ:IMNM) with a Hold and lowers the price target from $24 to $23.
benzinga.com Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30 Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.
businesswire.com Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced…
businesswire.com Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies,…
benzinga.com Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary…
benzinga.com Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.- benzinga.com Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026 Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE…